BIO-TECHNE Corp — Director's Dealing 2021

Nov 16, 2021

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: BIO-TECHNE Corp (TECH)
CIK: 0000842023
Period of Report: 2021-11-12

Reporting Person: Eansor Norman David (President-Protein Sciences)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2021-11-12	Common Stock	M	27159	$125.05	Acquired	28477	Direct
2021-11-12	Common Stock	S	700	$504.0864	Disposed	27777	Direct
2021-11-12	Common Stock	S	200	$504.78	Disposed	27577	Direct
2021-11-12	Common Stock	S	300	$502.99	Disposed	27277	Direct
2021-11-12	Common Stock	S	537	$504.1437	Disposed	26740	Direct
2021-11-12	Common Stock	S	400	$505.005	Disposed	26340	Direct
2021-11-12	Common Stock	S	4054	$502.7678	Disposed	22286	Direct
2021-11-12	Common Stock	S	9043	$503.6091	Disposed	13243	Direct
2021-11-12	Common Stock	S	8989	$504.3926	Disposed	4254	Direct
2021-11-12	Common Stock	S	2535	$505.4861	Disposed	1719	Direct
2021-11-12	Common Stock	S	401	$506.2399	Disposed	1318	Direct
2021-11-16	Common Stock	M	799	$125.05	Acquired	2117	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2021-11-12	Stock Options (Right to Buy)	$125.05	M	27159	Disposed	2024-08-09	Common Stock (27159)	Direct
2021-11-16	Stock Options (Right to Buy)	$125.05	M	799	Disposed	2024-08-09	Common Stock (799)	Direct

Holdings (Derivative)

Security	Exercise Price	Expiration	Underlying	Shares	Ownership
Stock Options (Right to Buy)	$177.32	2025-08-08	Common Stock (13550)	13550	Direct
Stock Options (Right to Buy)	$177.32	2025-08-08	Common Stock (18066)	18066	Direct
Restricted Stock Units	$		Common Stock (3151)	3151	Direct
Stock Options (Right to Buy)	$190.41	2026-08-07	Common Stock (15948)	15948	Direct
Stock Options (Right to Buy)	$190.41	2026-08-07	Common Stock (21265)	21265	Direct
Restricted Stock Units	$		Common Stock (2575)	2575	Direct
Stock Options (Right to Buy)	$267.87	2027-08-05	Common Stock (11488)	11488	Direct
Stock Options (Right to Buy)	$267.87	2027-08-05	Common Stock (15318)	15318	Direct
Stock Options (Right to Buy)	$267.87	2027-08-05	Common Stock (24975)	24975	Direct
Stock Options (Right to Buy)	$267.87	2027-08-05	Common Stock (24975.0)	24975.0	Direct
Restricted Stock Units	$		Common Stock (1556)	1556	Direct
Stock Options (Right to Buy)	$481.82	2028-08-06	Common Stock (6080)	6080	Direct
Stock Options (Right to Buy)	$481.82	2028-08-06	Common Stock (8107)	8107	Direct

Footnotes

F1: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $503.78 to $504.535, inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $502.62 to $503.33, inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

F3: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $503.77 to $504.745, inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

F4: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $504.97 to $505.11, inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

F5: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $502.11 to $503.10, inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

F6: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $503.11 to $504.107, inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

F7: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $504.13 to $505.11, inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

F8: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $505.13 to $506.07, inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

F9: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $506.20 to $506.275, inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

F10: Each restricted stock unit represents a contingent right to receive one share of Bio-Techne common stock.

F11: Fully exercisable.

F12: Options to purchase 4,517 shares vest on each of 8/8/2019 and 8/8/2020 and options to purchase 4,516 shares vest on each of 8/8/2021 and 8/8/2022.

F13: Vests in full or in part on 8/7/2022 if certain performance goals are achieved (or such later date as performance is certified by the Administrator).

F14: Options to purchase 5,317 shares vest on 8/7/2020 and options to purchase 5,316 shares vest on each of 8/7/2021, 8/7/2022 and 8/7/2023.

F15: Vests in full or in part on 8/5/2023 if certain performance goals are achieved (or such later date as performance is certified by the Administrator).

F16: Options to purchase 3,830 shares vest on each of 8/5/2021 and 8/5/2022 and options to purchase 3,829 shares vest on each of 8/5/2023 and 8/5/2024.

F17: Vests in full on the date performance of certain product revenue goals during the period of fiscal 2021-2023 is certified by the Administrator, in no event earlier than 8/5/2021.

F18: Options to purchase 8,325 shares vest on each of 8/5/2021, 8/5/2022 and 8/5/2023.

F19: Vests in full or in part on 8/6/2024 if certain performance goals are achieved (or such later date as performance is certified by the Administrator).

F20: Options to purchase 2,027 shares vest on each of 8/6/2022, 8/6/2023 and 8/6/2024 and options to purchase 2,026 shares vest on 8/6/2025.